Neurological Disorders

Department of Clinical Psychology, Capital Medical University, China

Publications

• Research Article   
  Single I.V.-ketamine Augmentation of Newly Initiated Venlafaxine Hydrocortisone for Treatment Resistant Depression: Randomized, Double blind Controlled Study Protocol
  Author(s): Yun Du, Ruobing Feng, Wenle Zhang, Jiexin Fang, Ke Ma, Encong Wang and Yongdong Hu*
  
  Background: The critical issue of treating Treatment Resistant Depression (TRD) is to improve antidepressant effect rapid onset and the recovery rates. Significant antidepressant effects of ketamine onset rapidly, but decays rapidly and repeated dosing increases the risks. This study aimed to explore the efficacy and safety of single intravenous ketamine, combined with venlafaxine’s hydrochloride for TRD. Methods: 32 patients with treatment resistant depression will be randomly selected to undergo a four weeks double blind treatment with single dose ketamine (0.5 mg/kg over 40 min) and venlafaxine hydrochloride (4 weeks) or midazolam maleate (0.045 mg/kg over 40 min) and venlafaxine hydrochloride (4 weeks). Depressive symptoms will be measured by the Montgomery–Asberg Depression Rating Scale (MADRS) and the 16 item Quick Inventor.. Read More»
  DOI: 10.4172/2329-6895.10.2.266

  Abstract HTML PDF